$376.61
1.18% today
NYSE, Nov 25, 07:14 pm CET
ISIN
US03073E1055
Symbol
COR

Cencora Stock price

$372.22
+39.51 11.88% 1M
+79.87 27.32% 6M
+147.54 65.67% YTD
+127.99 52.41% 1Y
+206.69 124.87% 3Y
+269.12 261.03% 5Y
+273.72 277.89% 10Y
+352.40 1,778.00% 20Y
NYSE, Closing price Mon, Nov 24 2025
+6.54 1.79%

New AI Insights on Cencora Insights AI Insights on Cencora

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$72.2b
Enterprise Value
$75.5b
Net debt
$3.3b
Cash
$4.4b
Shares outstanding
193.9m
Valuation (TTM | estimate)
P/E
46.5 | 21.1
P/S
0.2 | 0.2
EV/Sales
0.2 | 0.2
EV/FCF
23.5
P/B
41.3
Dividends
DPS
$2.20
Yield 1Y | 5Y
0.6% | 1.1%
Growth 1Y | 5Y
7.8% | 5.8%
Payout 1Y | 3Y
27.6% | 25.7%
Increased
20 Years
Financials (TTM | estimate)
Revenue
$321.3b | $345.5b
EBITDA
$4.8b | $5.1b
EBIT
$3.7b | $4.6b
Net Income
$1.6b | $3.4b
Free Cash Flow
$3.2b
Growth (TTM | estimate)
Revenue
9.3% | 7.5%
EBITDA
15.9% | 3.0%
EBIT
23.0% | 16.6%
Net Income
3.0% | 120.5%
Free Cash Flow
7.0%
Margin (TTM | estimate)
Gross
3.5%
EBITDA
1.5% | 1.5%
EBIT
1.2%
Net
0.5% | 1.0%
Free Cash Flow
1.0%
Financial Health
Equity Ratio
2.3%
Return on Equity
89.0%
ROCE
19.9%
ROIC
-
Debt/Equity
4.4
More
EPS
$8.0
FCF per Share
$16.5
Short interest
4.3%
Employees
44k
Rev per Employee
$7.3m
Show more

Is Cencora a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,053 stocks worldwide.

Cencora Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Cencora forecast:

16x Buy
73%
6x Hold
27%

Analyst Opinions

22 Analysts have issued a Cencora forecast:

Buy
73%
Hold
27%

Financial data from Cencora

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
321,333 321,333
9% 9%
100%
- Direct Costs 310,049 310,049
9% 9%
96%
11,284 11,284
15% 15%
4%
- Selling and Administrative Expenses 6,494 6,494
15% 15%
2%
- Research and Development Expense - -
-
-
4,790 4,790
16% 16%
1%
- Depreciation and Amortization 1,051 1,051
4% 4%
0%
EBIT (Operating Income) EBIT 3,739 3,739
23% 23%
1%
Net Profit 1,554 1,554
3% 3%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Cencora directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cencora Stock News

Positive
Seeking Alpha
18 days ago
Cencora is rated a Buy, with a target price of $392, driven by strong fundamentals and sector leadership. COR's stable business model, high cash flows, low debt, and shareholder-friendly policies make it attractive for conservative, long-term investors. Recent earnings showed double-digit profit growth, robust revenue from specialty drugs, and high predictability, supporting management's optimi...
Neutral
Seeking Alpha
20 days ago
Cencora, Inc. ( COR ) Q4 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Robert Mauch - President, CEO & Director James Cleary - Executive VP & CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michae...
Positive
Reuters
20 days ago
Cencora will invest over $1 billion through 2030 to expand its U.S. network, the drug distributor said on Wednesday, after forecasting adjusted profit for next year above Wall Street expectations.
More Cencora News

Company Profile

AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.

Head office United States
CEO Robert Mauch
Employees 44,000
Founded 1947
Website www.cencora.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today